

**DLS - OUTPATIENT (W/O EXTENDED CARE FACILITIES)  
ANTIMICROBIAL SUSCEPTIBILITY PROFILES (January 01 – June 30, 2007)**

(All sources)

**GRAM NEGATIVE SUSCEPTIBILITIES (Percent Susceptible)**

	Enterobacter aerogenes	Enterobacter cloacae	E. coli	E. coli ESBL	Klebsiella pneumoniae	Klebsiella pneumoniae ESBL	Pseudomonas aeruginosa	Serratia marcescens
Amoxicillin/CA	--	--	80	--	97	--	--	--
Ampicillin	--	--	59	--	--	--	--	--
Cefuroxime	--	--	93	--	98	--	--	--
Ceftriaxone	97	93	98	--	100	--	13	97
Cephalothin	--	--	59	--	91	--	--	--
Ciprofloxacin	98	97	87	7	99	75*	84	96
Gentamicin	98	97	94	84	99	25*	94	99
Minocycline	73	24	81	14	87	100*	--	85
Nalidixic Acid (u)	93	92	84	2	91	100*	--	93
Nitrofurantoin (u)	59	66	98	98	65	75*	--	--
Norfloxacin (u)	98	97	87	6	99	75*	84	96
Levofloxacin	98	97	87	7	99	75*	83	80
Tobramycin	100	98	97	90	99	75*	99	100
Trimeth-Sulfa	97	86	77	14	92	25*	--	97
<b>Total Isolates</b>	117	148	4857	158	760	3	590	74

**GRAM POSITIVE AND *H. influenzae* SUSCEPTIBILITIES (Percent Susceptible)**

	Staph. aureus	Staph. coag neg	Enterococcus	Haemophilus influenza
Ampicillin	--	--	99	79
Ceftriaxone	--	--	--	99
Cefazolin	57	51	--	--
Cefuroxime	--	--	--	99
Clindamycin **	81	77	--	--
Erythromycin	49	49	--	--
Gentamicin	97	91	--	--
Levofloxacin	80	69	--	--
Meropenem	--	--	--	100
Moxifloxacin	94	86	--	100
Nitrofurantoin (u)	100	99	99	--
Oxacillin	57	51	--	--
Penicillin	14	15	--	--
Rifampin ***	100	97	--	--
Tetracycline	94	79	16	70
Trimeth-Sulfa	97	81	--	83
Vancomycin	100	100	99	--
<b>Total Isolates</b>	2574	433	547	149

\* For total isolates of less than 10, the susceptibility percentage may not be clinically significant.

\*\* Clindamycin results have been verified by induction test.

\*\*\* Rifampin should not be used alone for treatment of staph infection.